A Study to Evaluate Efficacy of EB-PA as Protein Amplifier for Skeletal Muscle Strength & Growth

NCT ID: NCT06127849

Last Updated: 2024-02-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

138 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-28

Study Completion Date

2024-06-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present study is a randomized, placebo-controlled, double blinded study to evaluate efficacy of EB-PA as protein amplifier for skeletal muscle strength \& growth in males with active lifestyle. Approximately 160 subjects aged between ≥ 20 and ≤ 35 years will be screened and 138 participants are to be randomized. Both the IP and placebo study arms will have at least 40 completed subjects after accounting for the screening failure and dropout/withdrawal rate of 14% and 13 % respectively (Total 120 completers). The treatment duration for all the study subjects will be 30 days. The sustained effect of the product will be observed for next 7 days, wherein, the subjects will be abstaining from the protein and IP supplementation and will exercise at their ease.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Skeletal Muscle Strength & Growth

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Randomized, placebo-controlled, double-blinded study
Primary Study Purpose

OTHER

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Resistance Training + Placebo (Capsule) + Placebo (Sachet)

A sachet of 20 gms of Placebo dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.

One capsule of placebo to be taken 30 minutes after placebo sachet in the morning.

Group Type PLACEBO_COMPARATOR

Resistance Training + Placebo (Capsule) + Placebo (Sachet)

Intervention Type DIETARY_SUPPLEMENT

* Placebo sachet of 20 gms dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.
* One Placebo capsule to be taken 30 minutes after sachet in the morning.

Resistance Training + Whey protein (40 gms) + Placebo (Capsule)

A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.

One capsule of Placebo to be taken 30 minutes after whey protein in the morning.

Group Type ACTIVE_COMPARATOR

Resistance Training + Whey protein (40 gms) + Placebo (Capsule)

Intervention Type DIETARY_SUPPLEMENT

A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.

\- One Placebo capsule to be taken 30 minutes after whey protein in the morning

Resistance Training + Whey protein (40 gms) + EB-PA (500 mg)

A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.

One capsule of EB0-PA to be taken 30 minutes after whey protein in the morning.

Group Type ACTIVE_COMPARATOR

Resistance Training + Whey protein (40 gms) + EB-PA (500 mg)

Intervention Type DIETARY_SUPPLEMENT

* A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.
* One capsule of EB-PA to be taken 30 minutes after whey protein in the morning

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Resistance Training + Placebo (Capsule) + Placebo (Sachet)

* Placebo sachet of 20 gms dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.
* One Placebo capsule to be taken 30 minutes after sachet in the morning.

Intervention Type DIETARY_SUPPLEMENT

Resistance Training + Whey protein (40 gms) + Placebo (Capsule)

A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.

\- One Placebo capsule to be taken 30 minutes after whey protein in the morning

Intervention Type DIETARY_SUPPLEMENT

Resistance Training + Whey protein (40 gms) + EB-PA (500 mg)

* A sachet of 20 gms of Whey protein isolate (WPI) dissolved in 200-300 ml water. One sachet to be taken in the Morning and one in the evening.
* One capsule of EB-PA to be taken 30 minutes after whey protein in the morning

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males aged 20 - 35 years with active lifestyle with moderate physical activity level as per International Physical Activity Questionnaire.
* Recreationally gym goer with history of at least 1 month of endurance training (E.g.: functional exercises)
* Not participating in resistance type training (E.g.: external or body weight training) for ≥3 months prior to screening.
* Body mass index (BMI) 22 - 29.9 kg/ m2.
* Individuals with a 1-RM strength defined by Upper Body ≥ 25 Kgs and Lower Body ≥ 100 Kgs will be included in the study.
* Ready to refrain from caffeinated products and intense strength/ endurance exercise for 24 hrs prior to the exercise lab visit.
* Fasting Blood Glucose ≤ 110 mg/ dl.
* Systolic Blood Pressure ≤ 129 mmHg and Diastolic Blood Pressure ≤ 89 mmHg.
* TSH (thyroid stimulating hormone) ≥ 0.4 and ≤ 4.9 mIU/L.

Exclusion Criteria

* Engaged in structured weight training for more than 3 months prior to screening.
* Presence of chronic disease.
* Changes in body weight more than 4.5 kg (10 pounds) in the past three months as assessed by history.
* Subjects diagnosed with hypertension.
* Subjects who are diagnosed with Type I Diabetes Mellitus and Type II Diabetes Mellitus.
* History or presence of clinically significant renal, hepatic, endocrine, biliary, gastrointestinal, pancreatic or neurologic disorders.
* Allergy to whey protein or herbal ingredients.
* Subjects who have any other disease or condition, or are using any medication, that in the judgment of the investigator would put them at unacceptable risk for participation in the study or may interfere with evaluations in the study or noncompliance with treatment or visits.
* Subjects who have been part of a clinical study within 90 days prior to the screening.
* Subjects who have used whey or other supplemental proteins anytime in last 3 months.
Minimum Eligible Age

20 Years

Maximum Eligible Age

35 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Vedic Lifesciences Pvt. Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Dr. Khare's Clinic

Mumbai, Maharashtra, India

Site Status RECRUITING

Nirmala Clinic

Mumbai, Maharashtra, India

Site Status RECRUITING

Dr. Preeti Bawaskar's Clinic

Thāne, Maharashtra, India

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

India

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dr. Shalini Srivastava, MBBS, MD

Role: CONTACT

02242172300

Dr. Sonali Ghosh,, BAMS

Role: CONTACT

02242172300

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Dr. Sunira Khare, BHMS

Role: primary

+919664056580

Dr. Anand Yadav, BAMS, MD

Role: primary

+919594619143

Dr. Preeti Bawaskar, BAMS, MD

Role: primary

+919146680080

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EB/230701/EB-PA/SMSG

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.